In Conversation: Thomas Blake and Alison Demarest of Meridian BioGroup

Published on :

This year, Meridian BioGroup of Frederick, Maryland is celebrating its 15th year in business. The compliance, validation, and regulatory services provider has grown substantially in that time, and continues to put in the work to expand and improve. Co-founders Thomas Blake and Alison Demarest take pride in the work of their employees, Meridian’s work culture, and the expertise of the company in the biotech and pharmaceutical fields.

In Conversation: John Mumm, Chief Executive Officer, Deka Biosciences

Published on :

John Mumm is a serial biotechnology entrepreneur who, as a young researcher, demonstrated the importance of the cytokine, interleukin -10 (IL-10), in activating the immune system to destroy tumors. That research led to the use of Pegylated IL-10 to treat patients with pancreatic cancer and other solid tumors through his work at ARMO Biosciences, a company he founded and was later acquired by Eli Lilly in 2018.

In Conversation: Douglas Falk, Chief Executive Officer, Vita Therapeutics

Douglas Falk
Published on :

Vita Therapeutics, freshly infused with $32 million in financing, is advancing a novel approach to treating a localized form of muscular dystrophy with a cell therapy that combines a gene correction and induced pluripotent stem cell (iPSC) technology.

In Conversation: Sarah Miller, Vice President of Economic Development, BioHealth Innovation, Inc.

Published on :

After spending the past five years fostering economic development in Montgomery County, Sarah Miller is turning her attention to the biopharma industry and the BioHealth Capital Region. Starting May 3, Miller joined BioHealth Innovation, Inc. as Vice President of Economic Development.

In Conversation: Dr. Vipin K. Garg, CEO of Altimmune

Published on :

Dr. Vipin Garg, Altimmune’s (ALT) CEO since 2018 and a biotech industry veteran, has successfully led the publicly-traded company through these turbulent pandemic waters. We recently caught up with Dr. Garg to discuss the pandemic, Altimmune’s deep product pipeline, his unique perspectives on the BioHealth Capital Region (BHCR), and the state of the U.S. supply chain and biotech manufacturing ecosystem.

In Conversation: Bruce K. Redding Jr., CEO of Transdermal Specialties Global

Published on :

Founded by former NASA mission specialist Bruce K. Redding Jr., Transdermal Specialties Global (TSG) is attempting to revolutionize drug delivery. Redding, who holds over 60 patents, is the inventor of microencapsulation technology, which his company is leveraging to develop an insulin patch as a non-invasive, needleless method for diabetes treatment.

AstraZeneca’s Joe Sanchez Shares Vision for Growing the BioHealth Capital Region

Published on :

When AstraZeneca (AZ) announced in 2019 that it was officially retiring the MedImmune brand, questions naturally arose about whether the U.K. pharma giant would continue the legacy MedImmune support for the BioHealth Capital Region’s (BHCR) life science ecosystem.

In Conversation: Kevin Combs, CEO of Molecular Biologicals

Published on :

Kevin Combs, the CEO of Molecular Biologicals out of Charlottesville, Virginia, had a front-row seat to the BioHealth Capital Region’s (BHCR) ascendancy. He is now a vital part of the rise of CVille, the life science cluster within the BHCR that is blossoming in and around the University of Virginia (UVA).